FDA Commissioner talks fast-track research on psychedelic drugs

An executive order signed by President Trump aims to fast-track research into the therapeutic benefits of psychedelic compounds. This initiative is designed to accelerate clinical investigations while maintaining rigorous safety standards, directly addressing urgent mental health needs for veterans affected by PTSD, depression, and addiction. FDA Commissioner Dr. Martin A. Makary notes that the order empowers the FDA to issue national priority vouchers to streamline drug development pathways. This framework aims to reduce administrative delays and increase funding for studies on serotonin 2A agonist compounds. Rigorous phase 3 clinical trials, backed by significant medical interest, are positioned as a foundation for potentially transformative mental health treatments.